Polypill Strategy in Secondary Cardiovascular Prevention
The New England Journal of Medicine
31st Aug 2022

TAKE-HOME MESSAGE
In this randomized placebo-controlled trial involving 2499 participants who recently (within 6 months) experienced myocardial infarction (MI), treatment with a polypill (aspirin, ramipril, and atorvastatin) significantly reduced the risk of the primary composite outcome of cardiovascular death, nonfatal type 1 MI, nonfatal ischemic stroke, and urgent revascularization (HR, 0.76) compared with usual care. The treatment effects were consistent across all prespecified subgroups, with improved treatment adherence observed in the polypill group.

These findings support the use of a cardiovascular polypill after recent MI as part of an effective secondary prevention strategy to improve treatment adherence and clinical outcomes.

G Mohan